FindTrial
Sign In

The Effect of Content of Barley Beta-glucans in Bread on Postprandial Blood Sugar

The Effect of Content of Barley Beta-glucans in Bread on Postprandial Blood Sugar

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03878576
Acronym
ARRS-bGL-01
Enrollment
12
Registered
2019-03-18
Start date
2018-11-26
Completion date
2018-12-07
Last updated
2019-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glycemic Index

Keywords

Glycemic Index, glycemic response, bread, barley, beta-glucans, glucose level, continous glucose monitoring

Brief summary

The effect of content of barley beta-glucans in bread on postprandial blood sugar will be measured with open-label crossover study. Study will be conducted in Slovenia on 10-12 adult subjects who will test three barley beta-glucan containing bread formulations (food) in comparison with a reference white bread. Objective of the study is to investigate the influence of the content of barley beta-glucan in bread on glycaemic index (incremental area under the curve (IAUC) for the blood glucose response curve for barley beta-glucan containing breads in comparison to reference white bread.

Interventions

OTHERREFERENCE: white bread - BGL0 [RP]

Determination of glycemic response after consumption of BGL0.

OTHERTEST: b-glucan enriched bread - BGL2 [IP1]

Determination of glycemic response after consumption of BGL0.

OTHERTEST: b-glucan enriched bread - BGL3 [IP2]

Determination of glycemic response after consumption of BGL0.

OTHERTEST: b-glucan enriched bread - BGL4 [IP3]

Determination of glycemic response after consumption of BGL0.

Sponsors

Community Health Centre Ljubljana
CollaboratorOTHER
Slovenian Research Agency
CollaboratorOTHER
Valens Int. d.o.o., Slovenija
CollaboratorINDUSTRY
Institute of Nutrition, Slovenia (Nutris)
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Subject Informed consent form (ICF) is singed * Aged above 18 years at the time of the signature of ICF * No known food allergy or intolerance * No medications known to affect glucose tolerance - stable doses of oral contraceptives, acetylsalicylic acid, thyroxin, vitamins and mineral supplements or drugs to treat hypertension or osteoporosis are acceptable. * Willing to follow all study procedures, including attending all site visits (including sessions for blood sampling and use of CGM) * Body mass index (BMI) \> 25

Exclusion criteria

* Subject Informed consent form (ICF) is singed * Aged above 18 years at the time of the signature of ICF * No known food allergy or intolerance * No medications known to affect glucose tolerance - stable doses of oral contraceptives, acetylsalicylic acid, thyroxin, vitamins and mineral supplements or drugs to treat hypertension or osteoporosis are acceptable. * Willing to follow all study procedures, including attending all site visits (including sessions for blood sampling and use of CGM) * Body mass index (BMI) \> 25

Design outcomes

Primary

MeasureTime frameDescription
Change in glycaemic response (capillary blood glucose)2 hoursChange in incremental area under the curve (IAUC) the blood glucose response curve for barley beta-glucan containing breads (investigational products; IP1-3), in comparison to white bread (reference product; RP)

Other

MeasureTime frame
Glucose level as measured with continuous glucose monitor (CGM)up to 3 hours

Countries

Slovenia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026